MEDINDIA
English
हिन्दी
Español
français
中文
Email
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Icosapent.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Icosapent.
Acenocoumarol
Icosapent may increase the anticoagulant activities of Acenocoumarol.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Icosapent.
Alclometasone
The risk or severity of adverse effects can be increased when Alclometasone is combined with Icosapent.
Aldosterone
The risk or severity of adverse effects can be increased when Aldosterone is combined with Icosapent.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Icosapent.
Amcinonide
The risk or severity of adverse effects can be increased when Amcinonide is combined with Icosapent.
Androstenedione
The risk or severity of adverse effects can be increased when Androstenedione is combined with Icosapent.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Icosapent.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Icosapent.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Icosapent.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Icosapent.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Icosapent.
Bazedoxifene
Icosapent may increase the thrombogenic activities of Bazedoxifene.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Icosapent.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Icosapent.
Betamethasone
The risk or severity of adverse effects can be increased when Betamethasone is combined with Icosapent.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Icosapent.
Budesonide
The risk or severity of adverse effects can be increased when Budesonide is combined with Icosapent.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Icosapent.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Icosapent.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Icosapent.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Icosapent.
Chlorotrianisene
Icosapent may increase the thrombogenic activities of Chlorotrianisene.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Icosapent.
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Icosapent.
Citalopram
Citalopram may increase the antiplatelet activities of Icosapent.
Clobetasol
The risk or severity of adverse effects can be increased when Clobetasol is combined with Icosapent.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Icosapent.
Clobetasone
The risk or severity of adverse effects can be increased when Clobetasone is combined with Icosapent.
Clocortolone
The risk or severity of adverse effects can be increased when Clocortolone is combined with Icosapent.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Icosapent.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Icosapent.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Icosapent.
Deflazacort
The risk or severity of adverse effects can be increased when Deflazacort is combined with Icosapent.
Desonide
The risk or severity of adverse effects can be increased when Desonide is combined with Icosapent.
Desoximetasone
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Icosapent.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Icosapent.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Icosapent.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Icosapent.
Dexamethasone
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Icosapent.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Icosapent.
Dicumarol
Icosapent may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Icosapent may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Icosapent may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Diflorasone is combined with Icosapent.
Diflucortolone
The risk or severity of adverse effects can be increased when Difluocortolone is combined with Icosapent.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Icosapent.
Difluprednate
The risk or severity of adverse effects can be increased when Difluprednate is combined with Icosapent.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Icosapent.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Icosapent.
Duloxetine
Duloxetine may increase the antiplatelet activities of Icosapent.
Equol, (-)-
Icosapent may increase the thrombogenic activities of Equol.
Escitalopram
Escitalopram may increase the antiplatelet activities of Icosapent.
Estradiol
Icosapent may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Icosapent may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Icosapent may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Icosapent may increase the thrombogenic activities of Estradiol valerate.
Estriol
Icosapent may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Icosapent may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Icosapent may increase the thrombogenic activities of Estrogens, esterified.
Estrone
Icosapent may increase the thrombogenic activities of Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Icosapent.
Ethinyl Estradiol
Icosapent may increase the thrombogenic activities of Ethinyl Estradiol.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Icosapent.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Icosapent.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Icosapent.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Icosapent.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Icosapent.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Icosapent.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Icosapent.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Icosapent.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Icosapent.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Icosapent.
Fluindione
Icosapent may increase the anticoagulant activities of Fluindione.
Flumethasone
The risk or severity of adverse effects can be increased when Flumethasone is combined with Icosapent.
Flunisolide
The risk or severity of adverse effects can be increased when Flunisolide is combined with Icosapent.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Flunisolide is combined with Icosapent.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Icosapent.
Fluocinonide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Icosapent.
Fluocortolone
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Icosapent.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Icosapent.
Fluoxetine
Fluoxetine may increase the antiplatelet activities of Icosapent.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Icosapent.
Fluprednisolone
The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Icosapent.
Flurandrenolide
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Icosapent.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Icosapent.
Fluticasone
The risk or severity of adverse effects can be increased when Fluticasone is combined with Icosapent.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Icosapent.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Icosapent.
Fluvoxamine
Fluvoxamine may increase the antiplatelet activities of Icosapent.
Formestane
The risk or severity of adverse effects can be increased when Formestane is combined with Icosapent.
Genistein
Icosapent may increase the thrombogenic activities of Genistein.
Halcinonide
The risk or severity of adverse effects can be increased when Halcinonide is combined with Icosapent.
Halobetasol
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Icosapent.
Hydrocortisone
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Icosapent.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Icosapent.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Icosapent.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Icosapent.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Icosapent.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Icosapent.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Icosapent.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Icosapent.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Icosapent.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Icosapent.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Icosapent.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Icosapent.
Loteprednol
The risk or severity of adverse effects can be increased when Loteprednol is combined with Icosapent.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Icosapent.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icosapent.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Icosapent.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icosapent.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icosapent.
Medrysone
The risk or severity of adverse effects can be increased when Medrysone is combined with Icosapent.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Icosapent.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Icosapent.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Icosapent.
Mestranol
Icosapent may increase the thrombogenic activities of Mestranol.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Icosapent.
Milnacipran
Milnacipran may increase the antiplatelet activities of Icosapent.
Mometasone
The risk or severity of adverse effects can be increased when Mometasone is combined with Icosapent.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icosapent.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Icosapent.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icosapent.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Icosapent.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Icosapent.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Icosapent.
Nefazodone
Nefazodone may increase the antiplatelet activities of Icosapent.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Icosapent.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Icosapent.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Icosapent.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Icosapent.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Icosapent.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Icosapent.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Icosapent.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icosapent.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Icosapent.
Paramethasone
The risk or severity of adverse effects can be increased when Paramethasone is combined with Icosapent.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Icosapent.
Paroxetine
Paroxetine may increase the antiplatelet activities of Icosapent.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Icosapent.
Phenindione
Icosapent may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Icosapent may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Icosapent.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icosapent.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Icosapent.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Icosapent.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Icosapent.
Polyestradiol Phosphate
Icosapent may increase the thrombogenic activities of Polyestradiol phosphate.
Prasterone
The risk or severity of adverse effects can be increased when Prasterone is combined with Icosapent.
Prednicarbate
The risk or severity of adverse effects can be increased when Prednicarbate is combined with Icosapent.
Prednisolone
The risk or severity of adverse effects can be increased when Prednisolone is combined with Icosapent.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Icosapent.
Pregnenolone
The risk or severity of adverse effects can be increased when Pregnenolone is combined with Icosapent.
Promestriene
Icosapent may increase the thrombogenic activities of Promestriene.
Quinestrol
Icosapent may increase the thrombogenic activities of Quinestrol.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Icosapent.
Rimexolone
The risk or severity of adverse effects can be increased when Rimexolone is combined with Icosapent.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Icosapent.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Icosapent.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Icosapent.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Icosapent.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Icosapent.
Sertraline
Sertraline may increase the antiplatelet activities of Icosapent.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Icosapent.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Icosapent.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Icosapent.
synthetic conjugated estrogens, A
Icosapent may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Icosapent may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Icosapent.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Icosapent.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Icosapent.
Tibolone
Icosapent may increase the thrombogenic activities of Tibolone.
Tixocortol
The risk or severity of adverse effects can be increased when Tixocortol is combined with Icosapent.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Icosapent.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Icosapent.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Icosapent.
Triamcinolone
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Icosapent.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Icosapent.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Icosapent.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Icosapent.
Warfarin
Icosapent may increase the anticoagulant activities of Warfarin.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Icosapent.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Icosapent.
